Articles by author - Mark S Wagner

Clinical endocannabinoid deficiency (CECD) revisited: can this concept explain the therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?

Smith S, Wagner M.

Journal Article 2014; 35(3): 198-201 PubMed PMID: 24977967  Keywords:  Analgesics:therapeutic use, Animals, Cannabis, Drug Resistance:drug effects, Endocannabinoids:deficiency, Fatigue Syndrome, Chronic:drug therapy, Fibromyalgia:drug therapy, Humans, Irritable Bowel Syndrome:drug therapy, Lipid Metabolism, Inborn Errors:com.    Citation

OBJECTIVES: Ethan B. Russo's paper of December 1, 2003 explored the concept of a clinical endocannabinoid deficiency (CECD) underlying the.....

Read abstract  Full text PDF